 |
Spectrum Pharmaceuticals (SPPI) Patent Protection for FUSILEV (levoleucovorin) Through Dec. 31, 2019
Welcome to CRWENewswire, Stocks to Watch. I am Shalika Jayasekera Spectrum Pharmaceuticals Incorporated – symbol SPPI – reported that the FDA has granted FUSILEV (levoleucovorin) "Orphan Drug" exclusivity for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. In addition, FUSILEV therapeutic compositions are protected under a US Patent which expires at the end of December 2019 and the company has already filed a patent extension application. Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology. Thanks for joining me andhave a great day! For CRWE Newswire, Stocks to watch, I'm Shalika Jayasekera ********************************* THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at www.crwenewswire.com is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors <b>…</b>
|
From:crwenewswire
Views:
141  0
ratings |
| Time:01:12 | More inNews & Politics |